2019
Resolution of Sickle Cell Disease Manifestations in Patients Treated with Lentiglobin Gene Therapy: Updated Results from the Phase 1/2 Hgb-206 Group C Study
Kanter J, Tisdale J, Mapara M, Kwiatkowski J, Krishnamurti L, Schmidt M, Miller A, Pierciey F, Huang W, Ribeil J, Thompson A, Walters M. Resolution of Sickle Cell Disease Manifestations in Patients Treated with Lentiglobin Gene Therapy: Updated Results from the Phase 1/2 Hgb-206 Group C Study. Blood 2019, 134: 990. DOI: 10.1182/blood-2019-128894.Peer-Reviewed Original ResearchGroup C patientsRed blood cell transfusionBlood cell transfusionAdverse eventsC patientsMedian Hb levelHb levelsBluebird BioHematopoietic stem cellsCell transfusionLast visitBusulfan conditioningTotal hemoglobinHSC collectionGene therapyNon-hematologic gradeSerious adverse eventsLentiviral vectorsSickle cell diseaseStrong therapeutic effectVector copy numberCancer Research CenterAdditional patient dataAdvisory CommitteeSevere SCD
2010
Does Deep Venous Thrombosis as Primary Admitting Diagnosis Represent Different Etiologies and Disease Processes as Compared to DVT as Secondary Diagnoses (SD)?
Viswanathan P, Gandhi T, Krishnamurti L. Does Deep Venous Thrombosis as Primary Admitting Diagnosis Represent Different Etiologies and Disease Processes as Compared to DVT as Secondary Diagnoses (SD)? Blood 2010, 116: 1540. DOI: 10.1182/blood.v116.21.1540.1540.Peer-Reviewed Original ResearchDeep venous thrombosisCongestive heart failureSecondary diagnosisPrimary diagnosisDisease processHeart failureVenous thrombosisVenous catheterizationAtrial fibrillationEndotracheal intubationInvasive proceduresDiagnosis of DVTPacked red cell transfusionNational Inpatient Sample databaseSerious medical morbidityRed cell transfusionUrinary tract infectionAge group 45Serious medical illnessTime of admissionICD-9 codesICD-9 codingCell transfusionInitial admissionTract infections
2007
Use of Rituximab for Refractory Immune Cytopenias Associated with Autoimmune Lymphoproliferative Syndrome (ALPS).
Dale J, Price S, Tretler J, Aldridge P, Montague S, Davis J, Gill F, Hartman K, Stork L, Gnarra D, Krishnamurti L, Puck J, Fleisher T, Rao V. Use of Rituximab for Refractory Immune Cytopenias Associated with Autoimmune Lymphoproliferative Syndrome (ALPS). Blood 2007, 110: 1319. DOI: 10.1182/blood.v110.11.1319.1319.Peer-Reviewed Original ResearchAutoimmune lymphoproliferative syndromeALPS patientsMycophenolate mofetilRituximab therapyDouble-negative T lymphocytesALPS phenotypeNegative T lymphocytesUse of rituximabCompletion of therapyRed cell transfusionAdult male patientsNIH Clinical CenterLong-term riskDurable normalizationPneumococcal sepsisPrednisone pulsesRefractory ITPRituximab infusionRituximab useWeekly vincristineCell transfusionHepatitis CImmune thrombocytopeniaPalpable spleenPolysaccharide vaccine